Janne J. Turunen

Janne J. Turunen

Auto-generated profile, based on publicly available information

Janne J. Turunen

ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2012 in WIREs RNA
Verified
Journal Article
Open access
PDF file
JTJanne J. Turunen
Janne J. Turunen
ENElina H Niemelä
Elina H Niemelä
BVBhupendra Verma
Bhupendra Verma
MFMikko Frilander
Mikko Frilander
The removal of non‐coding sequences, introns, from the mRNA precursors is an essential step in eukaryotic gene expression. U12‐type introns are a minor subgroup of introns, distinct from the major or U2‐type introns. U12‐type introns are present in most eukaryotes but only account for less than 0.5% of all introns in any given genome. They are processed by a specific U12‐dependent spliceosome, which is similar to, but distinct from, the major spliceosome. U12‐type introns are spliced somewhat less efficiently than the major introns, and it is believed that this limits the expression of the genes containing such introns. Recent findings on the role of U12‐dependent splicing in development and human disease have shown that it can also affect multiple cellular processes not directly related to the functions of the host genes of U12‐type introns. At the same time, advances in understanding the regulation and phylogenetic distribution of the minor spliceosome are starting to shed light on how the U12‐type introns and the minor spliceosome may have evolved. WIREs RNA 2013, 4:61–76. doi: 10.1002/wrna.1141This article is categorized under: RNA Processing > Splicing Mechanisms

1 August 2021 in Molecular Therapy
Verified
Journal Article
Open access
KDKalyan Dulla
Kalyan Dulla
RSRalph Slijkerman
Ralph Slijkerman
HDHester C. van Diepen
Hester C. van Diepen
SASilvia Albert
Silvia Albert
MDMargo Dona
Margo Dona
Erwin Van WijkErwin Van Wijk
Erwin Van Wijk
Mutations in USH2A are among the most common causes of syndromic and non-syndromic retinitis pigmentosa (RP). The two most recurrent mutations in USH2A, c.2299delG and c.2276G>T, both reside in exon 13. Skipping of exon 13 from the USH2A transcript presents a potential treatment modality in which the resulting transcript is predicted to encode a slightly shortened usherin protein. Morpholino-induced skipping of ush2a exon 13 in zebrafish ush2armc1 mutants resulted in the production of usherinΔexon 13 protein and a completely restored retinal function. Antisense oligonucleotides were investigated for their potential to selectively induce human USH2A exon 13 skipping. Lead candidate QR-421a induced a concentration-dependent exon 13 skipping in iPSC-derived photoreceptor precursors from an Usher syndrome patient homozygous for the c.2299delG mutation. Mouse surrogate mQR-421a reached the retinal outer nuclear layer after a single intravitreal injection, and induced a detectable level of exon skipping until at least 6 months post injection. In conclusion, QR-421a-induced exon skipping proves to be a highly promising treatment option for RP caused by mutations in USH2A exon 13.

1 May 2008 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
JTJanne J. Turunen
Janne J. Turunen
CWCindy L. Will
Cindy L. Will
MGMichael Grote
Michael Grote
RLReinhard Lührmann
Reinhard Lührmann
MFMikko Frilander
Mikko Frilander
Little is currently known about proteins that make contact with the pre-mRNA in the U12-dependent spliceosome and thereby contribute to intron recognition. Using site-specific cross-linking, we detected an interaction between the U11-48K protein and U12-type 5' splice sites (5'ss). This interaction did not require branch point recognition and was sensitive to 5'ss mutations, suggesting that 48K interacts with the 5'ss during the first steps of prespliceosome assembly in a sequence-dependent manner. RNA interference-induced knockdown of 48K in HeLa cells led to reduced cell growth and the inhibition of U12-type splicing, as well as the activation of cryptic, U2-type splice sites, suggesting that 48K plays a critical role in U12-type intron recognition. 48K knockdown also led to reduced levels of U11/U12 di-snRNP, indicating that 48K contributes to the stability and/or formation of this complex. In addition to making contact with the 5'ss, 48K interacts with the U11-59K protein, a protein at the interface of the U11/U12 di-snRNP. These studies provide important insights into the protein-mediated recognition of the U12-type 5'ss, as well as functionally important interactions within the U11/U12 di-snRNP.

24 June 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HPHeli K. J. Pessa
Heli K. J. Pessa
CWCindy L. Will
Cindy L. Will
XMXiaojuan Meng
Xiaojuan Meng
CSClaudia Schneider
Claudia Schneider
NWNicholas James Watkins
Nicholas James Watkins
MFMikko Frilander
Mikko Frilander
Recently, it has been reported that there is a differential subcellular distribution of components of the minor U12-dependent and major U2-dependent spliceosome, and further that the minor spliceosome functions in the cytoplasm. To study the subcellular localization of the snRNA components of both the major and minor spliceosomes, we performedin situhybridizations with mouse tissues and human cells. In both cases, all spliceosomal snRNAs were nearly exclusively detected in the nucleus, and the minor U11 and U12 snRNAs were further shown to colocalize with U4 and U2, respectively, in human cells. Additionally, we examined the distribution of several spliceosomal snRNAs and proteins in nuclear and cytoplasmic fractions isolated from human cells. These studies revealed an identical subcellular distribution of components of both the U12- and U2-dependent spliceosomes. Thus, our data, combined with several earlier publications, establish that, like the major spliceosome, components of the U12-dependent spliceosome are localized predominantly in the nucleus.

1 March 2010 in Molecular Cell
Verified
Journal Article
Closed access
JVJens Verbeeren
Jens Verbeeren
ENElina H Niemelä
Elina H Niemelä
JTJanne J. Turunen
Janne J. Turunen
CWCindy L. Will
Cindy L. Will
JRJanne Ravantti
Janne Ravantti
MFMikko Frilander
Mikko Frilander

1 January 2014 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PDF file
SSSofia Stenler
Sofia Stenler
OWOscar Pb Wiklander
Oscar Pb Wiklander
MBMaria Badal-Tejedor
Maria Badal-Tejedor
JTJanne Turunen
Janne Turunen
JNJoel Nordin
Joel Nordin
PBPontus Blomberg
Pontus Blomberg
The minicircle (MC), composed of eukaryotic sequences only, is an interesting approach to increase the safety and efficiency of plasmid-based vectors for gene therapy. In this paper, we investigate micro-MC (miMC) vectors encoding small regulatory RNA. We use a construct encoding a splice-correcting U7 small nuclear RNA, which results in a vector of 650 base pairs (bp), as compared to a conventional 3600 bp plasmid carrying the same expression cassette. Furthermore, we construct miMCs of varying sizes carrying different number of these cassettes. This allows us to evaluate how size influences production, super-coiling, stability and efficiency of the vector. We characterize coiling morphology by atomic force microscopy and measure the resistance to shearing forces caused by an injector device, the Biojector. We compare the behavior of miMCs and plasmids in vitro using lipofection and electroporation, as well as in vivo in mice. We here show that when the size of the miMC is reduced, the formation of dimers and trimers increases. There seems to be a lower size limit for efficient expression. We demonstrate that miMCs are more robust than plasmids when exposed to shearing forces, and that they show extended expression in vivo.